Biofrontera Inc (BFRI)vsMerck & Company Inc (MRK)
BFRI
Biofrontera Inc
$0.93
+5.09%
HEALTHCARE · Cap: $11.97M
MRK
Merck & Company Inc
$146.35
+3.83%
HEALTHCARE · Cap: $360.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 144067% more annual revenue ($66.57B vs $46.17M). MRK leads profitability with a 4.8% profit margin vs -13.8%. BFRI earns a higher WallStSmart Score of 37/100 (F).
BFRI
Hold37
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BFRI.
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$146.35
$62.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.9% year-over-year
Reasonable price relative to book value
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BFRI
The strongest argument for BFRI centers on Revenue Growth, Price/Book. Revenue growth of 32.9% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : BFRI
The primary concerns for BFRI are EPS Growth, Market Cap, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
BFRI profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
BFRI carries more volatility with a beta of 0.88 — expect wider price swings.
BFRI is growing revenue faster at 32.9% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
BFRI scores higher overall (37/100 vs 36/100) and 32.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biofrontera Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Biofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?